Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide therapeutics for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide, an injectable mimetic of hepcidin that is in phase 3 clinical trials for the treatment of polycythemia vera; Icotrokinra, an orally delivered investigational drug which is in phase 3 clinical trials indicated to block biological pathways targeted by marketed injectable antibody drugs; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company also develops IL-17 oral peptide antagonist PN-88,1 an oral metabolic/obesity peptide program, and an oral hepcidin mimetic/ferroportin blocker that is in pre-clinical stage. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

Protagonist Therapeutics, Inc.

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Ligand Pharma (LGND), Protagonist Therapeutics (PT...

Analysts Offer Insights on Healthcare Companies: Ligand Pharma (LGND), Protagonist Therapeutics (PTGX) and Zoetis (ZTS)

Protagonist Therapeutics ( ($PTGX) ) has provided an announcement. On August 5, 2026, Protagonist reported second-quarter 2026 results that highlig...

Protagonist Therapeutics Highlights ICOTYDE Launch and Rusfertide Deal

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Protagonist Therapeutics (PTGX), UnitedHealth (UNH) and AnaptysBi...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	PTGX	$155.10	0.00%	444.79K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	PTGX	$155.10	0%	444.79K
3
4
5
6

PTGX

Get Protagonist Therapeutics, Inc. Data in Excel

Get Protagonist Therapeutics, Inc. Data in Excel